G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

04 Apr 2024 09:30:30 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2024 15:20:26 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:20:33 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

28 Feb 2024 05:30:52 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

27 Feb 2024 07:30:01 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

15 Feb 2024 07:30:28 By Nasdaq GlobeNewswire

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

12 Feb 2024 15:05:18 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

08 Jan 2024 05:45:52 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:17 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jan 2024 15:51:10 By Nasdaq GlobeNewswire

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

05 Dec 2023 08:26:20 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 15:27:24 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

29 Nov 2023 19:37:45 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

01 Nov 2023 05:30:53 By Nasdaq GlobeNewswire

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

27 Oct 2023 06:00:54 By Nasdaq GlobeNewswire

G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

18 Oct 2023 07:00:50 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

18 Oct 2023 06:30:06 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

16 Oct 2023 08:00:33 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 10:00:29 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2023 15:15:21 By Nasdaq GlobeNewswire